Agenix Limited

ASX:AGX ISIN:AU000000AGX2

 Agenix Limited (ASX:AGX) is a biopharmaceutical company based in Melbourne, Australia. Through its wholly owned subsidiaries, Agen Biomedical (headquartered in Melbourne, Australia) and Agenix Biopharmaceutical (in Shanghai, China), the Company has a strategic goal of building and developing a line of therapeutic and imaging products. 
 
    

View in Other Languages

News

Agenix Limited (ASX:AGX) Chairmans Address to Shareholders at 2011 Annual General Meeting

🕔10/31/2011 10:36:00 AM 11945

Agenix Limited (ASX:AGX) is pleased to provide Chairman's Address to shareholders at 2011 Annual General Meeting.

Read Full Article

Agenix Limited (ASX:AGX) Signed New China Agreements to Advance Lead Drug Candidate and New Product Pipeline

🕔10/13/2011 8:26:00 AM 8606

Agenix Limited (ASX:AGX) today confirmed it had signed two new agreements with its strategic partners in China covering the commercialisation of new drug candidates, the sharing of resources, expertise and completion of pre-clinical toxicology tests for its new hepatitis B drug in China.

Read Full Article

Agenix Limited (ASX:AGX) Showcase Promising New Low-Risk Hepatitis Drug for China Market at Bio Korea 2011

🕔9/30/2011 2:32:45 PM 9492

Agenix Limited (ASX:AGX) confirmed its promising new hepatitis B drug, AGX-1009, shared the same active compound as Gilead's blockbuster drug, Viread, which is widely used to treat HIV and hepatitis throughout Asia.

Read Full Article

Asian Activities Report for September 27, 2011: General Mining Corporation (ASX:GMM) to Acquire a New Mongolian Project for Coal Exploration

🕔9/27/2011 12:00:07 PM 11549

Asian Activities Report for September 27, 2011 includes: General Mining Corporation Limited (ASX:GMM) has signed an agreement to acquire a coal exploration licence in Mongolia; Aphrodite Gold Limited (ASX:AQQ) announced further robust gold intersections at its Aphrodite Gold Deposit; Agenix Limited (ASX:AGX) has filed a patent application for its hepatitis B drug AGX-1009; Manas Resources Limited (ASX:MSR) reported a 20% increase in its Shambesai Total Mineral Resource to 766,000 ounces of gold; Infotech Enterprises Limited (BOM:532175) announced its partnership with Software Engineering Institute.

Read Full Article

Asian Activities Report for June 8, 2011: Agenix (ASX:AGX) On Track To Begin Clinical Trials In China For The New Hepatitis B Drug

🕔6/8/2011 12:00:11 PM 12053

Asian Activities Report for June 8, 2011 includes: Agenix (ASX:AGX) is on track to begin clinical trials in China for its lead Hepatitis B drug; Central Asia Resources Limited (ASX:CVR) reported gold resource increase to 124,000 ounces at Dalabai Gold Project; Tanami Gold NL (ASX:TAM) announced a further substantial increase in its gold Mineral Resources to 2.30 million ounces of gold; Corazon Mining Limited (ASX:CZN) confirmed the existence of a high-grade nickel/copper sulphide discovery at the Lynn Lake nickel sulphide project in Canada.

Read Full Article

Aegis Equities Research Announce Health and Life Science Review, August 2006

🕔8/15/2006 2:42:55 PM 13903

The August 2006 edition of our Health & Life Science Quarterly Blue Book profiles niche life sciences companies, with a focus on company strategies, key projects and significant milestones.

Read Full Article
###

47,336 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 11) (Last 30 Days: 68) (Since Published: 12993) 

Company Data

    Headquarters
  • Ground Floor
    156 Collins Street
    Melbourne VIC 3000
    Australia
  • Telephone
  • 1300-132-551 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 1987/10/08 
  • Homepage
  • www.agenix.com

More News Results

  • 2024/03/11: February 2024 Investment Update*
  • 2024/03/08: Half Year Accounts*
  • 2024/03/05: Units on Issue & Redemptions - February 2024*
  • 2024/02/29: Disclosure of Portfolio Holdings December 2023*
  • 2024/02/28: Product Disclosure Statement - AGX1*
*refer to company website

Presentations

Download Presentation